IN2012DN03042A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03042A
IN2012DN03042A IN3042DEN2012A IN2012DN03042A IN 2012DN03042 A IN2012DN03042 A IN 2012DN03042A IN 3042DEN2012 A IN3042DEN2012 A IN 3042DEN2012A IN 2012DN03042 A IN2012DN03042 A IN 2012DN03042A
Authority
IN
India
Prior art keywords
neuropeptide
obesity
diabetes
substituents
fragments
Prior art date
Application number
Other languages
English (en)
Inventor
Karin Conde-Knape
Waleed Danho
Nader Fotouhi
David C Fry
Wajiha Khan
Anish Konkar
Cristina Martha Rondinone
Joseph Swistok
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IN2012DN03042A publication Critical patent/IN2012DN03042A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57545Neuropeptide Y
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IN3042DEN2012 2009-10-13 2010-10-08 IN2012DN03042A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25089609P 2009-10-13 2009-10-13
PCT/EP2010/065060 WO2011045232A2 (en) 2009-10-13 2010-10-08 Neuropeptide-2 receptor (y-2r) agonists

Publications (1)

Publication Number Publication Date
IN2012DN03042A true IN2012DN03042A (de) 2015-07-31

Family

ID=43478048

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3042DEN2012 IN2012DN03042A (de) 2009-10-13 2010-10-08

Country Status (7)

Country Link
US (1) US20110172147A1 (de)
EP (1) EP2488195A2 (de)
JP (1) JP2013507414A (de)
CN (1) CN102596228A (de)
CA (1) CA2776302A1 (de)
IN (1) IN2012DN03042A (de)
WO (1) WO2011045232A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
RU2641198C3 (ru) 2012-03-22 2021-12-10 Ново Нордиск А/С Композиции glp-1 пептидов и их получение
EP2708243A1 (de) * 2012-09-17 2014-03-19 OntoChem GmbH Rezeptor-Ligand-verbundene zytotoxische Moleküle
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
US9085637B2 (en) 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
MA41898A (fr) * 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
WO2016198682A1 (en) 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof
IL275778B2 (en) 2018-02-02 2023-12-01 Novo Nordisk As Solid compounds that make up glp-1 agonist n-8-2-hydroxybenzoyl salt
CN109678930B (zh) * 2018-12-05 2022-04-29 西北工业大学 聚乙二醇修饰的npff及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB779829A (en) 1953-11-20 1957-07-24 Ciba Ltd Polyglycol ethers and their manufacture
BE667886A (de) 1965-04-23
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5962263A (en) * 1998-01-08 1999-10-05 Incyte Pharmaceuticals, Inc. Human membrane recycling proteins
US20030229013A1 (en) * 2001-12-07 2003-12-11 Shih-Kwang Wu Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
UA103758C2 (ru) 2004-07-19 2013-11-25 Биокон Лимитед Конъюгаты олигомеров инсулина, их композиции и применение
WO2006049681A2 (en) * 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) * 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
WO2006091505A2 (en) * 2005-02-24 2006-08-31 Bayer Pharmaceuticals Corporation Neuropeptide y receptor agonists
ES2381497T3 (es) * 2005-12-07 2012-05-28 F. Hoffmann-La Roche Ag Agonistas del receptor del neuropéptido-2
CA2699366C (en) * 2007-09-11 2013-12-03 Nicolai Bovin Peptide-lipid constructs and their use in diagnostic and therapeutic applications
KR20110097807A (ko) * 2008-11-05 2011-08-31 에프. 호프만-라 로슈 아게 뉴로펩티드-2-수용체(y-2r) 작용제 및 이의 용도

Also Published As

Publication number Publication date
CA2776302A1 (en) 2011-04-21
JP2013507414A (ja) 2013-03-04
CN102596228A (zh) 2012-07-18
WO2011045232A3 (en) 2011-06-16
EP2488195A2 (de) 2012-08-22
WO2011045232A2 (en) 2011-04-21
US20110172147A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
TW200806311A (en) Neuropeptide-2 receptor-agonists
IN2012DN03042A (de)
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
HK1158192A1 (en) Piperidine gpcr agonists
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
MX2009011802A (es) Imidazoquinolinas con propiedades inmunomoduladoras.
GB0812642D0 (en) Compounds
MX2011012122A (es) Derivados de tiofeno.
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
IN2012DN01233A (de)
IN2012DN03182A (de)
IN2012DN02139A (de)
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2012000704A (es) Agonistas de gpr119.
MY160728A (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2009013501A (es) Compuestos piperidinicos y sus usos.
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes